European Journal of Vascular & Endovascular Surgery
Volume 39 , Pages S1-S4 , March 2010

World Federation of Vascular Societies: Presidential Address

  • H. Sillesen

      Affiliations

    • Corresponding Author InformationTel.: +45 35452105; fax: +45 35452303.

Received 30 November 2009 ,Accepted 5 December 2009.

References 

  1. Heart protection study. Lancet. 2002;360:17–22
  2. Antithrombotic Trialists Collaboration. BMJ. 2002;324:71–86
  3. Østergren J, Sleight P, Daganeis G, et al. Impact of ramipril on patients with evidence of clinical or sub-clinical peripheral arterial disease. Eur Heart J. 2004;25:17–24
  4. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II: inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J VAsc Endovasc Surg. 2007;33:S1
  5. Poldermans D, Boersma E, Bax JJ, Thompson IR, Paelinck B, Van Deven LL, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J. 2001;22:e1353–e1358
  6. Møller AM, Villebro N, Pedersen T, Tønnesen H. Lancet. 2002;359:114–117
  7. Schouten O, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl Med. 2009;361:980–989

PII: S1078-5884(09)00613-3

doi: 10.1016/j.ejvs.2009.12.006

European Journal of Vascular & Endovascular Surgery
Volume 39 , Pages S1-S4 , March 2010

Article Tools

* Image Usage & Resolution